[go: up one dir, main page]

MX2019011982A - Compuesto macrociclico y sus usos. - Google Patents

Compuesto macrociclico y sus usos.

Info

Publication number
MX2019011982A
MX2019011982A MX2019011982A MX2019011982A MX2019011982A MX 2019011982 A MX2019011982 A MX 2019011982A MX 2019011982 A MX2019011982 A MX 2019011982A MX 2019011982 A MX2019011982 A MX 2019011982A MX 2019011982 A MX2019011982 A MX 2019011982A
Authority
MX
Mexico
Prior art keywords
compound
macrociclic
pharmaceutically acceptable
fac
activity
Prior art date
Application number
MX2019011982A
Other languages
English (en)
Other versions
MX389899B (es
Inventor
Ito Ken
Kira Kazunobu
Kishi Yoshito
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/814,105 external-priority patent/US9938288B1/en
Application filed by Harvard College filed Critical Harvard College
Publication of MX2019011982A publication Critical patent/MX2019011982A/es
Publication of MX389899B publication Critical patent/MX389899B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Display Devices Of Pinball Game Machines (AREA)

Abstract

La presente invención proporciona el novedoso Compuesto (1) que tiene efectos de remodelación vascular tumoral y/o actividad anti-FAC (fibroblastos asociados al cáncer), o una de sus sales farmacéuticamente aceptables, opcionalmente en un portador farmacéuticamente aceptable, y sus usos médicos.
MX2019011982A 2017-04-05 2018-04-03 Compuesto macrocíclico y sus usos. MX389899B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762482030P 2017-04-05 2017-04-05
US201762526677P 2017-06-29 2017-06-29
US201762586416P 2017-11-15 2017-11-15
US15/814,105 US9938288B1 (en) 2017-04-05 2017-11-15 Macrocyclic compound and uses thereof
PCT/US2018/025887 WO2018187331A1 (en) 2017-04-05 2018-04-03 Macrocyclic compound and uses thereof

Publications (2)

Publication Number Publication Date
MX2019011982A true MX2019011982A (es) 2019-11-08
MX389899B MX389899B (es) 2025-03-20

Family

ID=63104288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011982A MX389899B (es) 2017-04-05 2018-04-03 Compuesto macrocíclico y sus usos.

Country Status (33)

Country Link
US (2) US11725015B2 (es)
EP (2) EP3606928B1 (es)
JP (4) JP7168580B2 (es)
KR (2) KR102836514B1 (es)
CN (2) CN115093429B (es)
AU (2) AU2018250147B2 (es)
CA (1) CA3056945A1 (es)
CL (1) CL2019002854A1 (es)
CO (1) CO2019011538A2 (es)
DK (1) DK3606928T3 (es)
EC (1) ECSP19075677A (es)
ES (1) ES2931533T3 (es)
HR (1) HRP20221385T1 (es)
HU (1) HUE060466T2 (es)
IL (2) IL288991B2 (es)
JO (1) JOP20190234B1 (es)
LT (1) LT3606928T (es)
MA (1) MA48027B1 (es)
MD (1) MD3606928T2 (es)
MX (1) MX389899B (es)
PE (1) PE20200602A1 (es)
PH (1) PH12019502197A1 (es)
PL (1) PL3606928T3 (es)
PT (1) PT3606928T (es)
RS (1) RS63755B1 (es)
SA (1) SA519410259B1 (es)
SG (1) SG11201908603PA (es)
SI (1) SI3606928T1 (es)
SM (1) SMT202200455T1 (es)
TW (3) TWI863657B (es)
UA (1) UA124399C2 (es)
WO (1) WO2018187331A1 (es)
ZA (1) ZA201906279B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017520586A (ja) 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
TWI863657B (zh) 2017-04-05 2024-11-21 哈佛大學校長及研究員協會 巨環化合物及其用途
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
IL295588B2 (en) * 2017-07-06 2024-03-01 Harvard College Synthesis of halichondrins
WO2019099646A1 (en) * 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
DE4229425A1 (de) 1992-09-03 1994-03-10 Kodak Ag Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US5352804A (en) * 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
JP2818381B2 (ja) 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
CN1216051C (zh) 1998-06-17 2005-08-24 卫材株式会社 大环类似物及其使用和制备的方法
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP2001305734A (ja) 2000-04-20 2001-11-02 Fuji Photo Film Co Ltd 光重合性組成物
JP2003261447A (ja) 2002-03-07 2003-09-16 Kyosei Seiyaku Kk 抗腫瘍剤
CA3028453C (en) 2004-06-03 2021-07-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
WO2006076100A2 (en) 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
ES2530021T3 (es) 2007-03-07 2015-02-25 Interdigital Technology Corporation Método y aparato para generar y tratar una unidad de datos de protocolo MAC-ehs
WO2008157490A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
CN101883763B (zh) 2007-10-03 2016-04-20 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
JP5134686B2 (ja) 2007-11-16 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂアナログ合成のための新規な中間体及び前記中間体に用いるための新規な脱スルホニル化反応
MX2010010902A (es) 2008-04-04 2010-12-21 Eisai R&D Man Co Ltd Analogos de halicondrina b.
EP2528914B1 (en) 2010-01-26 2014-06-11 Eisai R&D Management Co., Ltd. Furo[3,2-b]pyrane derivatives useful in the synthesis of halichondrin b analogs
EP2663337A4 (en) 2011-01-10 2014-06-11 Harvard College METHOD OF DELIVERING AGENTS IN CELLS BY BACTERIAL TOXINE
WO2012147900A1 (en) * 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
WO2013086634A1 (en) 2011-12-16 2013-06-20 Alphora Research Inc. Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl) propanol derivatives and intermediates useful thereof
IN2014MN01521A (es) 2011-12-29 2015-05-01 Alphora Res Inc
AU2013239290B2 (en) 2012-03-30 2017-08-03 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein
KR20150003156A (ko) * 2012-11-30 2015-01-08 항조우 질록스 파마 컴퍼니 리니티드 라파마이신 유사체 및 이의 제조 방법
EP2997017B1 (en) 2013-05-15 2017-08-09 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
EP3016957A4 (en) 2013-07-03 2016-11-30 Alphora Res Inc SYNTHETIC METHOD FOR THE PRODUCTION OF CYCLIC C1-KETO ANALOGUE OF HALICHONDRIN B AND USEFUL INTERMEDIATE PRODUCTS, INCLUDING INTERMEDIATE PRODUCTS WITH -SO2- (P-TOLYL) GROUPS
US9783549B2 (en) * 2013-11-04 2017-10-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B
CA2931788C (en) 2013-12-06 2022-05-24 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
JP2017520586A (ja) * 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
EP3191479B1 (en) 2014-09-09 2020-04-08 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
US10308661B2 (en) 2015-05-07 2019-06-04 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
MX387267B (es) * 2015-07-01 2025-03-18 Signalchem Lifesciences Corp Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico.
SG11201806515RA (en) 2016-03-02 2018-09-27 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
MX2019009779A (es) 2017-02-20 2019-12-19 Polyphor Ag Combinaciones farmaceuticas para tratar cancer.
US9938288B1 (en) * 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
TWI863657B (zh) 2017-04-05 2024-11-21 哈佛大學校長及研究員協會 巨環化合物及其用途
WO2019009956A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College SUMMARY OF MEDIUM MEDIATED KETONE
IL295588B2 (en) 2017-07-06 2024-03-01 Harvard College Synthesis of halichondrins
US20230135188A1 (en) 2017-07-06 2023-05-04 President And Fellows Of Harvard College Fe/cu-mediated ketone synthesis
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
WO2019099646A1 (en) * 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US20230357286A1 (en) 2020-07-24 2023-11-09 President And Fellows Of Harvard College Ketone synthesis and applications

Also Published As

Publication number Publication date
WO2018187331A8 (en) 2018-12-06
RU2019135531A (ru) 2021-05-05
CO2019011538A2 (es) 2020-02-28
TWI781163B (zh) 2022-10-21
EP3606928B1 (en) 2022-09-07
SA519410259B1 (ar) 2022-09-11
TW202321259A (zh) 2023-06-01
ES2931533T3 (es) 2022-12-30
IL288991B2 (en) 2023-12-01
SI3606928T1 (sl) 2023-02-28
DK3606928T3 (da) 2022-11-28
US11725015B2 (en) 2023-08-15
EP4119563A3 (en) 2023-04-05
CN115093429B (zh) 2024-08-30
US20230406863A1 (en) 2023-12-21
CL2019002854A1 (es) 2019-12-27
IL288991B1 (en) 2023-08-01
JP2022153392A (ja) 2022-10-12
JP7168580B2 (ja) 2022-11-09
IL288991A (en) 2022-02-01
JP6366873B1 (ja) 2018-08-08
BR112019020208A2 (pt) 2020-04-22
JP7400025B2 (ja) 2023-12-18
WO2018187331A1 (en) 2018-10-11
IL269788A (en) 2019-11-28
HUE060466T2 (hu) 2023-03-28
SG11201908603PA (en) 2019-10-30
TW202426457A (zh) 2024-07-01
JP2024028872A (ja) 2024-03-05
TW201902902A (zh) 2019-01-16
KR20240023674A (ko) 2024-02-22
JP7696416B2 (ja) 2025-06-20
AU2018250147A1 (en) 2019-10-03
TWI863657B (zh) 2024-11-21
PT3606928T (pt) 2022-12-05
ECSP19075677A (es) 2020-01-31
AU2018250147B2 (en) 2022-09-29
LT3606928T (lt) 2022-12-12
EP3606928A1 (en) 2020-02-12
AU2022291454B2 (en) 2024-03-28
MX389899B (es) 2025-03-20
MA48027B1 (fr) 2022-12-30
RS63755B1 (sr) 2022-12-30
IL269788B (en) 2022-01-01
RU2019135531A3 (es) 2021-09-07
JOP20190234B1 (ar) 2023-09-17
HRP20221385T1 (hr) 2023-01-06
AU2022291454A1 (en) 2023-02-16
JP2018177774A (ja) 2018-11-15
PE20200602A1 (es) 2020-03-10
KR102634732B1 (ko) 2024-02-13
UA124399C2 (uk) 2021-09-08
TWI836643B (zh) 2024-03-21
CN110831946A (zh) 2020-02-21
KR102836514B1 (ko) 2025-07-22
SMT202200455T1 (it) 2023-01-13
ZA201906279B (en) 2021-01-27
US20210261566A1 (en) 2021-08-26
JP2020513021A (ja) 2020-04-30
PL3606928T3 (pl) 2023-02-06
CN115093429A (zh) 2022-09-23
CN110831946B (zh) 2022-06-21
CA3056945A1 (en) 2018-10-11
EP4119563A2 (en) 2023-01-18
PH12019502197A1 (en) 2020-12-07
JOP20190234A1 (ar) 2019-10-03
KR20190137121A (ko) 2019-12-10
MD3606928T2 (ro) 2022-12-31
US12421248B2 (en) 2025-09-23

Similar Documents

Publication Publication Date Title
ECSP19075677A (es) Compuesto macrocíclico y sus usos
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2020009115A (es) Inhibidores de cd73.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2020003845A (es) Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
MX2017009449A (es) Inhibidor jak.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
IN2014CH00393A (es)
CY1124706T1 (el) Συνδυασμοι και χρησεις αυτων
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
WO2019099646A8 (en) Macrocyclic compounds and uses thereof
MX2021007477A (es) Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer.
MX2018007231A (es) Una composicion antimicrobiana.
MX2020003816A (es) Compuesto de heteroarilo con contenido de nitrogeno, y su uso farmaceutico.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
MX381598B (es) Combinación farmacéutica que comprende un parvovirus y bevacizumab.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
AR111357A1 (es) Compuestos macrocíclico y sus usos
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
AR103484A1 (es) Triptólido y sus derivados en el tratamiento de tumores y patologías precancerosas de la piel
CY1123076T1 (el) Ενωσεις βενζο-ν-υδροξυ αμιδιου που εχουν αντικαρκινικη δραστikothta